Ttps Dual Strip Dpi Ellipta Platform00 01 00 14 Still005

Ergo

Breathe easy

Robust, scaleable, available.

Case studies

Az

TTP develops dose counter for AstraZeneca’s Symbicort® inhaler

TTP's approach reduced risk and uncertainty in R&D and ultimately led to a better product: a top-mounted dose counter which achieves high levels of reliability and has fewer parts than competitor devices.

Read more


Hovione

Hovione - TwinCaps® inhaler

In response to the 2006 global threat of a flu pandemic, Hovione was asked to develop and manufacture an inhalation device capable of delivering an influenza anti-viral drug.

Read the full story


Khaler Hero

K-Haler® inhaler taking innovation into production

TTP routinely creates and applies new technologies, and much of our success is down to the fact that we are able to turn these new technologies into manufacturable products.

Full details here

Iso

ISO13485 accredited

TTP's Quality Management System (QMS) is certified by BSI to comply to ISO13485:2016, and the system incorporates ISO14971 risk management and specific requirements for human factors. Our QMS covers the whole design process from initial ideas through to transfer to manufacturing.

Our record with BSI audits speaks for itself: we have had an average of two minor non-conformities per year across all of our activities over the last five years, including across the 2003 to 2016 transition. We have never had a major non-conformity over the ten years the QMS has been in place. This record is objectively exceptional – TTP is amongst the very best. 

Our thinking

User Final

Remote user testing for medical device development: advantages as well as challenges abound

Remote user testing allowed us to substantially accelerate the development of the CoVent™ ventilator. Dan Lock reviews the impact of social distancing on user research and finds that many of our necessary adaptations will continue to have value. Yet, each new study challenges us to come up with new approaches to inform medical device development.

Read Dan Lock's blog here

Barrier

Complex generics pharmaceutical devices: scaling the barriers to entry

Many generics companies have experienced the challenges of getting a “complex generic” to market firsthand. But, argues David Cottenden, there are device strategies to stack the odds in your favour…

Read the blog here

Adherence

Design for adherence: a model for predicting and improving medication adherence

Medication adherence is often studied after a drug or delivery device has been developed, but what if we were able to predict levels of adherence for a particular drug delivery device during development?

Read the full story

Get in touch

We use cookies to improve your experience on our site. To find out more, read our updated privacy policy. More information.

{